Regulatory milestones

Abraxis BioScience Inc. (NASDAQ:ABII) gained $0.05 to $74.42 last week after Japan's Ministry of Health, Labor and Welfare (MHLW) approved Abraxane nab-paclitaxel to treat breast cancer. Taiho Pharmaceutical Co. Ltd., a subsidiary of Otsuka Pharmaceutical Co. Ltd. (Tokyo:4768), has Japanese rights to the albumin stabilized nanoparticle formulation of paclitaxel.